Literature DB >> 25138228

Understanding incretins.

Adam M Deane1, Palle B Jeppesen.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25138228     DOI： 10.1007/s00134-014-3435-0

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  15 in total

1.  Dysglycaemia in the critically ill and the interaction of chronic and acute glycaemia with mortality.

Authors:  Mark P Plummer; Rinaldo Bellomo; Caroline E Cousins; Christopher E Annink; Krishnaswamy Sundararajan; Benjamin A J Reddi; John P Raj; Marianne J Chapman; Michael Horowitz; Adam M Deane
Journal:  Intensive Care Med       Date:  2014-04-24       Impact factor: 17.440

Review 2.  Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.

Authors:  C F Deacon; E Mannucci; B Ahrén
Journal:  Diabetes Obes Metab       Date:  2012-04-24       Impact factor: 6.577

3.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

Authors:  M A Nauck; M M Heimesaat; C Orskov; J J Holst; R Ebert; W Creutzfeldt
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

4.  Management of hyperglycemia with the administration of intravenous exenatide to patients in the cardiac intensive care unit.

Authors:  Mohammad Abuannadi; Mikhail Kosiborod; Lisa Riggs; John A House; Mitchell S Hamburg; Kevin F Kennedy; Steven P Marso
Journal:  Endocr Pract       Date:  2013 Jan-Feb       Impact factor: 3.443

5.  The glucoregulatory benefits of glucagon-like peptide-1 (7-36) amide infusion during intensive insulin therapy in critically ill surgical patients: a pilot study.

Authors:  Panagis Galiatsatos; B Robert Gibson; Atoosa Rabiee; Olga Carlson; Josephine M Egan; Richard P Shannon; Dana K Andersen; Dariush Elahi
Journal:  Crit Care Med       Date:  2014-03       Impact factor: 7.598

6.  Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes.

Authors:  Adam M Deane; Matthew J Summers; Antony V Zaknic; Marianne J Chapman; Robert J L Fraser; Anna E Di Bartolomeo; Judith M Wishart; Michael Horowitz
Journal:  Crit Care       Date:  2011-01-21       Impact factor: 9.097

Review 7.  Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetes Care       Date:  2012-04-19       Impact factor: 19.112

Review 8.  Incretins and the intensivist: what are they and what does an intensivist need to know about them?

Authors:  Mark P Plummer; Marianne J Chapman; Michael Horowitz; Adam M Deane
Journal:  Crit Care       Date:  2014-02-20       Impact factor: 9.097

9.  The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study.

Authors:  Adam M Deane; Marianne J Chapman; Robert J L Fraser; Carly M Burgstad; Laura K Besanko; Michael Horowitz
Journal:  Crit Care       Date:  2009-05-13       Impact factor: 9.097

10.  Diabetic status and the relation of the three domains of glycemic control to mortality in critically ill patients: an international multicenter cohort study.

Authors:  James S Krinsley; Moritoki Egi; Alex Kiss; Amin N Devendra; Philipp Schuetz; Paula M Maurer; Marcus J Schultz; Roosmarijn T M van Hooijdonk; Morita Kiyoshi; Iain M J Mackenzie; Djillali Annane; Peter Stow; Stanley A Nasraway; Sharon Holewinski; Ulrike Holzinger; Jean-Charles Preiser; Jean-Louis Vincent; Rinaldo Bellomo
Journal:  Crit Care       Date:  2013-03-01       Impact factor: 9.097
View more
  1 in total

1.  Systematic review of incretin therapy during peri-operative and intensive care.

Authors:  Abraham H Hulst; Mark P Plummer; Markus W Hollmann; J Hans DeVries; Benedikt Preckel; Adam M Deane; Jeroen Hermanides
Journal:  Crit Care       Date:  2018-11-14       Impact factor: 9.097
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.